Swan Winifred L 4
4 · NxStage Medical, Inc. · Filed Feb 25, 2019
Insider Transaction Report
Form 4
Swan Winifred L
SVP and General Counsel
Transactions
- Disposition to Issuer
Common Stock
2019-02-21$30.00/sh−13,077$392,310→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2019-02-21−11,542→ 0 totalExercise: $11.03From: 2013-04-04Exp: 2023-03-03→ Common Stock (11,542 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2019-02-21−49,529→ 0 totalExercise: $14.66From: 2014-04-10Exp: 2024-03-09→ Common Stock (49,529 underlying) - Disposition to Issuer
Restricted Stock Unit
2019-02-21−9,314→ 0 totalExercise: $0.00From: 2018-03-09Exp: 2020-03-09→ Common Stock (13,971 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2019-02-21−53,315→ 0 totalExercise: $16.66From: 2015-04-03Exp: 2025-03-02→ Common Stock (53,315 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2019-02-21−71,509→ 0 totalExercise: $15.58From: 2016-04-09Exp: 2026-03-08→ Common Stock (71,509 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2019-02-21−39,884→ 0 totalExercise: $27.89From: 2017-04-09Exp: 2027-03-08→ Common Stock (39,884 underlying)
Footnotes (3)
- [F1]Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash.
- [F2]This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price.
- [F3]These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share.